Q-omics provides the consensus-scored CDRT15P11 profile across patient tissues and cancer cell-line models. CDRT15P11 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CDRT15P11 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, CDRT15P11 RNA expression shows 6,037 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, LUSC, and STAD as cancer lineages where CDRT15P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDRT15P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDRT15P11 survival associations across molecular data types. CDRT15P11 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDRT15P11 RNA expression–survival associations across cancer types. High CDRT15P11 expression shows unfavorable associations in DLBC, CHOL, UCS, STAD, THCA and PCPG. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for CDRT15P11 RNA expression.
This table summarizes CDRT15P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CDRT15P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDRT15P11 shows higher tumor expression in LUSC. The LUSC box plot shows higher CDRT15P11 RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p = .022).
This table shows molecular features associated with CDRT15P11 in patient tissues and cancer cell lines. In patient samples, CDRT15P11 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
